The effect of early life events on glucose levels in first-episode psychosis

Garcia-Rizo, Clemente ; Cabrera, Bibiana ; Bioque, Miquel ; Mezquida, Gisela ; Lobo, Antonio (Universidad de Zaragoza) ; Gonzalez-Pinto, Ana ; Diaz-Caneja, Covadonga M. ; Corripio, Iluminada ; Vieta, Eduard ; Baeza, Inmaculada ; Garcia-Portilla, Maria Paz ; Gutierrez-Fraile, Miguel ; Rodriguez-Jimenez, Roberto ; Garriga, Marina ; Fernandez-Egea, Emilio ; Bernardo, Miguel ; PEPs Group

Resumen: First episode of psychosis (FEP) patients display a wide variety of metabolic disturbances at onset, which might underlie these patients’ increased morbidity and early mortality. Glycemic abnormalities have been previously related to pharmacological agents; however, recent research highlights the impact of early life events. Birth weight (BW), an indirect marker of the fetal environment, has been related to glucose abnormalities in the general population over time. We aim to evaluate if BW correlates with glucose values in a sample of FEP patients treated with different antipsychotics. Two hundred and thirty-six patients were included and evaluated for clinical and metabolic variables at baseline and at 2, 6, 12, and 24 months of follow-up. Pearson correlations and linear mixed model analysis were conducted to analyze the data. Antipsychotic treatment was grouped due to its metabolic risk profile. In our sample of FEP patients, BW was negatively correlated with glucose values at 24 months of follow-up [r=-0.167, p=0.037]. BW showed a trend towards significance in the association with glucose values over the 24-month period (F=3.22; p=0.073) despite other confounders such as age, time, sex, body mass index, antipsychotic type, and chlorpromazine dosage. This finding suggests that BW is involved in the evolution of glucose values over time in a cohort of patients with an FEP, independently of the type of pharmacological agent used in treatment. Our results highlight the importance of early life events in the later metabolic outcome of patients.

Idioma: Inglés

DOI: 10.3389/fendo.2022.983792

Año: 2022

Publicado en: Frontiers in Endocrinology 13 (2022), [9 pp.]
ISSN: 1664-2392

Factor impacto JCR: 5.2 (2022)

Categ. JCR: ENDOCRINOLOGY & METABOLISM rank: 36 / 144 = 0.25 (2022) - Q1 - T1

Factor impacto CITESCORE: 5.6 - Medicine (Q1)

Factor impacto SCIMAGO: 1.278 - Endocrinology, Diabetes and Metabolism (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI20-00661
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI08-0208
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI11-00325
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI14-00612

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)